Last reviewed · How we verify
Ropivacaine and Dexmedetomidine
Ropivacaine and Dexmedetomidine, marketed by B.P. Koirala Institute of Health Sciences, is a combination drug currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports market stability. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Ropivacaine and Dexmedetomidine |
|---|---|
| Sponsor | B.P. Koirala Institute of Health Sciences |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Suprainguinal Fascia Iliaca Block With vs Without Dexmedetomidine (PHASE4)
- PENG Block Variants With Dexamethasone and Dexmedetomidine in Older Adults (NA)
- Three Variants of the PENG Block With and Without Perineural Adjuvants in Older Adults (NA)
- Contrast and Anesthetic Level With Lumbar Erector Spinae Plan (ESP) Block (NA)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- PENG Block With Dexmedetomidine in Older Adults (NA)
- Tubeless Strategy in Lung Transplantation: A Prospective Single-Arm Study (NA)
- Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: